Market open
RxSight/$RXST
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Ticker
$RXST
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
374
Website
RxSight Metrics
BasicAdvanced
$2B
Market cap
-
P/E ratio
-$1.00
EPS
1.19
Beta
-
Dividend rate
Price and volume
Market cap
$2B
Beta
1.19
52-week high
$66.54
52-week low
$22.91
Average daily volume
391K
Financial strength
Current ratio
14.335
Quick ratio
13.203
Long term debt to equity
3.879
Total debt to equity
4.146
Interest coverage (TTM)
-173.64%
Management effectiveness
Return on assets (TTM)
-10.58%
Return on equity (TTM)
-17.01%
Valuation
Price to revenue (TTM)
16.221
Price to book
7.32
Price to tangible book (TTM)
7.32
Price to free cash flow (TTM)
-52.848
Growth
Revenue change (TTM)
71.90%
Earnings per share change (TTM)
-48.73%
3-year revenue growth (CAGR)
87.53%
3-year earnings per share growth (CAGR)
115.45%
What the Analysts think about RxSight
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for RxSight stock.
RxSight Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RxSight Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RxSight News
AllArticlesVideos
RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024
GlobeNewsWire·2 weeks ago
RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences
GlobeNewsWire·3 months ago
Investing In The Future Of Cataract Surgery: The RxSight Advantage
Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for RxSight stock?
RxSight (RXST) has a market cap of $2B as of November 08, 2024.
What is the P/E ratio for RxSight stock?
The price to earnings (P/E) ratio for RxSight (RXST) stock is 0 as of November 08, 2024.
Does RxSight stock pay dividends?
No, RxSight (RXST) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next RxSight dividend payment date?
RxSight (RXST) stock does not pay dividends to its shareholders.
What is the beta indicator for RxSight?
RxSight (RXST) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.